Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information u	
TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING	Docket Number (Optional)
REJECTION OVER A "PRIOR" PATENT	434-US-PCT
In re Application of: Ask Puschi, et al.	
Application No.: 10/551,883	
Filed: November 29, 2005	
For: 4-(2-PHENYLSULFANYL-PHENYL)-PIPERIDINE DERIVATIVES AS SEROTONIN REUPTAKE	INHIBITORS
The owner', <u>H. Lundesck AIS</u> of 100 percent interest in the except as provided below, the terminal part of the statutory term of any patent granted on the instant in the expiration date of the full statutory term prior patent two. <u>7,144,884</u> as the term of said and 173, and as the term of said and 173, and as the term of said man of 173, and as the term of said incomparing the said that the prior patent is presently abordanch by any terminal disclaimer. The or greater than the price that it and the process that the process of the said that the said	application which would extend beyond prior patent is defined in 35 U.S.C. 154 where hereby agrees that any patent so rior patent are commonly owned. This uccessors or assigns.
In making the above disclaimer, the owner does not disclaim the ferminal part of the term of any patent would extend to the expiration date of the full saturbuy term as defined in 35 U.S.C. 154 and 173 of the patent is presently shortened by any terminal disclaimer," in the event that said prior patent later: expires for failure by ay a maintenance tree; is held unenforceable; is locard invalid by a court of competent jurisdiction; is statutorly disclaimed in whole or terminally disclaimed under 37 CFR 1.321;	granted on the instant application that prior patent, "as the term of said prior
has all claims canceled by a reexamination certificate; is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened b	y any terminal disclaimer.
Check either box 1 or 2 below, if appropriate.	
 For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization. 	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Tille 18 of the United States Code and that such willful false statements may leopardize the validity of the application or any patient issued thereon.	
The undersigned is an attorney or agent of record. Reg. No54,010	
/Margaret M. Buck, Reg. #54,010/ Signature	April 3, 2009 Date
Margaret M. Buck Typed or printed name	
-	201-350-0790 Telephone Number
Terminal disclaimer fee under 37 CFR 1.20(d) included.	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	

This obligation of information is required by 97 CFF1 1321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially, a powered by 24 CFF 137 CFF